Hapten-specific naïve B cells are biomarkers of vaccine efficacy against drugs of abuse

Journal of Immunological Methods

Volumn 405, Issue , 2014, Pages 74-86

  Taylor, J J ^a   Laudenbach, M ^b   Tucker, A M ^b   Jenkins, M K ^a   Pravetoni, M ^a,b  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b MINNEAPOLIS MEDICAL RESEARCH FOUNDATION   (United States)

Author keywords

Addiction; Antibodies; B cell; Prescription opioids; Vaccine

Indexed keywords

6OXY KLH VACCINE; 8HYDROC KLH VACCINE; AMINOOXYACETIC ACID; CARRIER PROTEIN; DRUGS USED IN THE TREATMENT OF ADDICTION; HAPTEN; HYDROCODONE; IMMUNOGLOBULIN G ANTIBODY; OXYCODONE; UNCLASSIFIED DRUG; VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY BLOOD LEVEL; ANTIBODY SPECIFICITY; ANTIBODY TITER; ANTIGEN SPECIFICITY; ARTICLE; B LYMPHOCYTE; B LYMPHOCYTE ACTIVATION; CELL POPULATION; CONTROLLED STUDY; DERIVATIZATION; DRUG ABUSE; DRUG DESIGN; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG MECHANISM; DRUG SCREENING; DRUG SYNTHESIS; FLOW CYTOMETRY; IMMUNIZATION; LYMPHOCYTE COUNT; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; STRUCTURE ANALYSIS; VACCINATION; VACCINE FAILURE;

ANIMALIA; MUS;

ADDICTION; ANTIBODIES; B CELL; PRESCRIPTION OPIOIDS; VACCINE;

ANIMALS; ANTIBODIES; B-LYMPHOCYTES; BRAIN; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HAPTENS; HUMANS; HYDROCODONE; IMMUNOGLOBULIN G; MALE; MICE; MICE, INBRED BALB C; MOLECULAR STRUCTURE; OUTCOME ASSESSMENT (HEALTH CARE); OXYCODONE; REPRODUCIBILITY OF RESULTS; STREET DRUGS; SUBSTANCE-RELATED DISORDERS; VACCINATION; VACCINES;

EID: 84897439342     PISSN: 00221759     EISSN: 18727905     Source Type: Journal    
DOI: 10.1016/j.jim.2014.01.010     Document Type: Article

References (41)

1. Astronomo R.D., Burton D.R. Carbohydrate vaccines: developing sweet solutions to sticky situations?. Nat. Rev. Drug Discov. Apr 2010, 9(4):308.
2. Bell J., Gray D. Antigen-capturing cells can masquerade as memory B cells. J. Exp. Med. 2003, 197(10):1233.
3. Cai X., Whitfield T., Moreno A.Y., et al. Probing the effects of hapten stability on cocaine vaccine immunogenicity. Mol. Pharm. 2013, 10(11):4176-4184. (Publication Date (Web): August 8, 2013). 10.1021/mp400214w.
4. Fahim R.E., Kessler P.D., Kalnik M.W. Therapeutic vaccines against tobacco addiction. Expert Rev. Vaccines Mar 2013, 12(3):333.
5. Frasca D., Diaz A., Romero M., et al. Unique biomarkers for B-cell function predict the serum response to pandemic H1N1 influenza vaccine. Int. Immunol. Mar 2012, 24(3):175.
6. Frasca D., Diaz A., Romero M., et al. Young and elderly patients with type 2 diabetes have optimal B cell responses to the seasonal influenza vaccine. Vaccine 2013, 31(35):3603.
7. Grova N., Prodhomme E.J., Schellenberger M.T., Farinelle S., Muller C.P. Modulation of carcinogen bioavailability by immunisation with benzo[a]pyrene-conjugate vaccines. Vaccine 2009, 27(31):4142.
8. Haney M., Gunderson E.W., Jiang H., Collins E.D., Foltin R.W. Cocaine-specific antibodies blunt the subjective effects of smoked cocaine in humans. Biol. Psychiatry 2010, 67(1):59.
9. Harmey D., Griffin P.R., Kenny P.J. Development of novel pharmacotherapeutics for tobacco dependence: progress and future directions. Nicotine Tob. Res. Nov 2012, 14(11):1300.
10. Hatsukami D.K., Rennard S., Jorenby D., et al. Safety and immunogenicity of a nicotine conjugate vaccine in current smokers. Clin. Pharmacol. Ther. Nov 2005, 78(5):456.
11. Hatsukami D.K., Jorenby D.E., Gonzales D., et al. Immunogenicity and smoking-cessation outcomes for a novel nicotine immunotherapeutic. Clin. Pharmacol. Ther. Mar 2011, 89(3):392.
12. Keyler D.E., Roiko S.A., Earley C.A., Murtaugh M.P., Pentel P.R. Enhanced immunogenicity of a bivalent nicotine vaccine. Int. Immunopharmacol. Nov 2008, 8(11):1589.
13. Kinsey B.M., Kosten T.R., Orson F.M. Anti-cocaine vaccine development. Expert Rev. Vaccines Sep 2010, 9(9):1109.
14. Koff W.C., Burton D.R., Johnson P.R., et al. Accelerating next-generation vaccine development for global disease prevention. Science May 31 2013, 340(6136):1232910.
15. Kosten T.R., Rosen M., Bond J., et al. Human therapeutic cocaine vaccine: safety and immunogenicity. Vaccine 2002, 20(7-8):1196.
16. Martell B.A., Orson F.M., Poling J., et al. Cocaine vaccine for the treatment of cocaine dependence in methadone-maintained patients: a randomized, double-blind, placebo-controlled efficacy trial. Arch. Gen. Psychiatry Oct 2009, 66(10):1116.
17. Maxwell J.C. The prescription drug epidemic in the United States: a perfect storm. Drug Alcohol Rev. May 2011, 30(3):264.
18. McHeyzer-Williams L.J., McHeyzer-Williams M.G. Antigen-specific memory B cell development. Annu. Rev. Immunol. 2005, 23:487.
19. Montoya I.D. Advances in the development of biologics to treat drug addictions and overdose. Adicciones 2012, 24(2):95.
20. National Survey on Drug Use and Health: National Findings 2011.
21. Orson F.M., Rossen R.D., Shen X., Lopez A.Y., Wu Y., Kosten T.R. Spontaneous development of IgM anti-cocaine antibodies in habitual cocaine users: effect on IgG antibody responses to a cocaine cholera toxin B conjugate vaccine. Am. J. Addict. Mar-Apr 2013, 22(2):169.
22. Pape K.A., Taylor J.J., Maul R.W., Gearhart P.J., Jenkins M.K. Different B cell populations mediate early and late memory during an endogenous immune response. Science 2011, 331(6021):1203.
23. Pauli N.T., Henry Dunand C.J., Wilson P.C. Exploiting human memory B cell heterogeneity for improved vaccine efficacy. Front. Immunol. 2011, 2:77.
24. Pravetoni M., Le Naour M., Harmon T., Tucker A., Portoghese P.S., Pentel P.R. An oxycodone conjugate vaccine elicits oxycodone-specific antibodies that reduce oxycodone distribution to brain and hot-plate analgesia. J. Pharmacol. Exp. Ther. Apr 2012, 341(1):225-232. (Epub 2012 Jan 18). 10.1124/jpet.111.189506.
25. Pravetoni M., Keyler D.E., Pidaparthi R.R., et al. Structurally distinct nicotine immunogens elicit antibodies with non-overlapping specificities. Biochem. Pharmacol. 2012, 83(4):543.
26. Pravetoni M., Raleigh M.D., Le Naour M., et al. Co-administration of morphine and oxycodone vaccines reduces the distribution of 6-monoacetylmorphine and oxycodone to brain in rats. Vaccine 2012, 30(31):4617.
27. Pravetoni M., Le Naour M., Tucker A.M., et al. Reduced antinociception of opioids in rats and mice by vaccination with immunogens containing oxycodone and hydrocodone haptens. J. Med. Chem. 2013, 56(3):915.
28. Pryde D.C., Jones L.H., Gervais D.P., et al. Selection of a novel anti-nicotine vaccine: influence of antigen design on antibody function in mice. PLoS One 2013, 8(10):e76557.
29. Shen X.Y., Orson F.M., Kosten T.R. Vaccines against drug abuse. Clin. Pharmacol. Ther. Jan 2012, 91(1):60.
30. Shorter D., Kosten T.R. Novel pharmacotherapeutic treatments for cocaine addiction. BMC Med. 2011, 9:119.
31. Skolnick P., Volkow N.D. Addiction therapeutics: obstacles and opportunities. Biol. Psychiatry 2012, 72(11):890.
32. Stotts A.L., Dodrill C.L., Kosten T.R. Opioid dependence treatment: options in pharmacotherapy. Expert. Opin. Pharmacother. Aug 2009, 10(11):1727.
33. Sundling C., Phad G., Douagi I., Navis M., Karlsson Hedestam G.B. Isolation of antibody V(D)J sequences from single cell sorted rhesus macaque B cells. J. Immunol. Methods 2012, 386(1-2):85.
34. Tars K., Kotelovica S., Lipowsky G., et al. Different binding modes of free and carrier-protein-coupled nicotine in a human monoclonal antibody. J. Mol. Biol. 2012, 415(1):118.
35. Taylor J.J., Jenkins M.K., Pape K.A. Heterogeneity in the differentiation and function of memory B cells. Trends Immunol. Dec 2012, 33(12):590.
36. Taylor J.J., Pape K.A., Jenkins M.K. A germinal center-independent pathway generates unswitched memory B cells early in the primary response. J. Exp. Med. 2012, 209(3):597.
37. Taylor J.J., Martinez R.J., Titcombe P.J., et al. Deletion and anergy of polyclonal B cells specific for ubiquitous membrane-bound self-antigen. J. Exp. Med. 2012, 209(11):2065.
38. Tonstad S., Heggen E., Giljam H., et al. Niccine(R), a nicotine vaccine, for relapse prevention: a phase II, randomized, placebo-controlled, multicenter clinical trial. Nicotine Tob. Res. Sep 2013, 15(9):1492-1504. (Epub 2013 Mar 7). 10.1093/ntr/ntt003.
39. UNODC. World Drug Report, 2012. 2012.
40. Wilson P.C., Andrews S.F. Tools to therapeutically harness the human antibody response. Nat. Rev. Immunol. Oct 2012, 12(10):709.
41. Wrammert J., Smith K., Miller J., et al. Rapid cloning of high-affinity human monoclonal antibodies against influenza virus. Nature 2008, 453(7195):667.